Bionic nanovesicles sequentially treat flaps with different durations of ischemia by thrombolysis and prevention of ischemia-reperfusion injury
Flap transplantation is a critical part of the recovery process for patients who have undergone tumor resection. However, the process of ischemia-reperfusion injury during flap transplantation and the resulting high-risk thrombotic microenvironment are unavoidable. In this study, based on an in-dept...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | Materials Today Bio |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590006425000870 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540381143629824 |
|---|---|
| author | Linzhong Yang Yuanchen Liu Cheng Tao Zichen Cao Shilin Guo Zheng Wei Yanyi Wang Tao Liu Lin Chen Ke Xiong Xingyu Luo Jianchuan Ran Wei Han |
| author_facet | Linzhong Yang Yuanchen Liu Cheng Tao Zichen Cao Shilin Guo Zheng Wei Yanyi Wang Tao Liu Lin Chen Ke Xiong Xingyu Luo Jianchuan Ran Wei Han |
| author_sort | Linzhong Yang |
| collection | DOAJ |
| description | Flap transplantation is a critical part of the recovery process for patients who have undergone tumor resection. However, the process of ischemia-reperfusion injury during flap transplantation and the resulting high-risk thrombotic microenvironment are unavoidable. In this study, based on an in-depth investigation of the ischemia time and prognosis of transplanted flaps, we propose a treatment strategy using sequential thrombolysis and ischemia-reperfusion injury prevention tailored to the ischemia time. This approach is designed to minimize the likelihood of thrombus formation and to clear the intravascular inflammatory microenvironment, with the aim of preventing and salvaging ischemic flaps. Specifically, we have successfully constructed a clinical-grade bionic vesicle, UK-PBNZ@PM, a system that cleverly incorporates drug components that have been widely used in clinical applications, thereby demonstrating a high degree of clinical translational potential. Prussian blue nano-enzymes (PBNZ) are the core component and demonstrate remarkable efficacy against ischemia-reperfusion injury due to their excellent biocompatibility, robust reactive oxygen species (ROS) scavenging capacity and anti-inflammatory properties. At the same time, urokinase (UK), a key pharmaceutical agent in antithrombotic therapy, has been effectively incorporated into the system, enhancing its ability to prevent and treat thrombosis. In addition, the integration of a platelet membrane (PM) has endowed the bionic vesicles with precise targeting and delivery capabilities, ensuring that the drugs can reach the lesion directly and facilitate efficient and precise release. The experimental results demonstrated that an ischemia-timed strategy can not only efficiently promote thrombolysis, but also effectively remove harmful elements in the microenvironment of ischemia-reperfusion injury. This discovery represents a new and promising approach to the treatment of thrombosis. |
| format | Article |
| id | doaj-art-36d48e2904394d7291f23c6cfc8b96ce |
| institution | Kabale University |
| issn | 2590-0064 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Materials Today Bio |
| spelling | doaj-art-36d48e2904394d7291f23c6cfc8b96ce2025-02-05T04:32:35ZengElsevierMaterials Today Bio2590-00642025-04-0131101529Bionic nanovesicles sequentially treat flaps with different durations of ischemia by thrombolysis and prevention of ischemia-reperfusion injuryLinzhong Yang0Yuanchen Liu1Cheng Tao2Zichen Cao3Shilin Guo4Zheng Wei5Yanyi Wang6Tao Liu7Lin Chen8Ke Xiong9Xingyu Luo10Jianchuan Ran11Wei Han12Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Jiangsu, 210008, ChinaDepartment of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Jiangsu, 210008, ChinaDepartment of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Jiangsu, 210008, ChinaCapital Medical University, Beijing Key Lab Tooth Regenerate & Function Reconstruct, Beijing Lab Oral Health, 10 You Men Wai Xi Tou Tiao, Beijing, 100069, ChinaDepartment of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Jiangsu, 210008, ChinaPediatric Dentistry, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing, Jiangsu, 210008, ChinaDepartment of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Jiangsu, 210008, ChinaDepartment of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Jiangsu, 210008, ChinaDepartment of Orthopedics, Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, 225300, ChinaDepartment of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Jiangsu, 210008, ChinaDepartment of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Jiangsu, 210008, ChinaDepartment of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Jiangsu, 210008, China; Corresponding author. Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Research Institute of Stomatology, Nanjing University, Nanjing, 210008, China.Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Jiangsu, 210008, China; Corresponding author. Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Research Institute of Stomatology, Nanjing University, Nanjing, 210008, China.Flap transplantation is a critical part of the recovery process for patients who have undergone tumor resection. However, the process of ischemia-reperfusion injury during flap transplantation and the resulting high-risk thrombotic microenvironment are unavoidable. In this study, based on an in-depth investigation of the ischemia time and prognosis of transplanted flaps, we propose a treatment strategy using sequential thrombolysis and ischemia-reperfusion injury prevention tailored to the ischemia time. This approach is designed to minimize the likelihood of thrombus formation and to clear the intravascular inflammatory microenvironment, with the aim of preventing and salvaging ischemic flaps. Specifically, we have successfully constructed a clinical-grade bionic vesicle, UK-PBNZ@PM, a system that cleverly incorporates drug components that have been widely used in clinical applications, thereby demonstrating a high degree of clinical translational potential. Prussian blue nano-enzymes (PBNZ) are the core component and demonstrate remarkable efficacy against ischemia-reperfusion injury due to their excellent biocompatibility, robust reactive oxygen species (ROS) scavenging capacity and anti-inflammatory properties. At the same time, urokinase (UK), a key pharmaceutical agent in antithrombotic therapy, has been effectively incorporated into the system, enhancing its ability to prevent and treat thrombosis. In addition, the integration of a platelet membrane (PM) has endowed the bionic vesicles with precise targeting and delivery capabilities, ensuring that the drugs can reach the lesion directly and facilitate efficient and precise release. The experimental results demonstrated that an ischemia-timed strategy can not only efficiently promote thrombolysis, but also effectively remove harmful elements in the microenvironment of ischemia-reperfusion injury. This discovery represents a new and promising approach to the treatment of thrombosis.http://www.sciencedirect.com/science/article/pii/S2590006425000870Bionic nanovesiclesFlap repairIschemia-reperfusion injuryThrombus-targetedFlap survival time |
| spellingShingle | Linzhong Yang Yuanchen Liu Cheng Tao Zichen Cao Shilin Guo Zheng Wei Yanyi Wang Tao Liu Lin Chen Ke Xiong Xingyu Luo Jianchuan Ran Wei Han Bionic nanovesicles sequentially treat flaps with different durations of ischemia by thrombolysis and prevention of ischemia-reperfusion injury Materials Today Bio Bionic nanovesicles Flap repair Ischemia-reperfusion injury Thrombus-targeted Flap survival time |
| title | Bionic nanovesicles sequentially treat flaps with different durations of ischemia by thrombolysis and prevention of ischemia-reperfusion injury |
| title_full | Bionic nanovesicles sequentially treat flaps with different durations of ischemia by thrombolysis and prevention of ischemia-reperfusion injury |
| title_fullStr | Bionic nanovesicles sequentially treat flaps with different durations of ischemia by thrombolysis and prevention of ischemia-reperfusion injury |
| title_full_unstemmed | Bionic nanovesicles sequentially treat flaps with different durations of ischemia by thrombolysis and prevention of ischemia-reperfusion injury |
| title_short | Bionic nanovesicles sequentially treat flaps with different durations of ischemia by thrombolysis and prevention of ischemia-reperfusion injury |
| title_sort | bionic nanovesicles sequentially treat flaps with different durations of ischemia by thrombolysis and prevention of ischemia reperfusion injury |
| topic | Bionic nanovesicles Flap repair Ischemia-reperfusion injury Thrombus-targeted Flap survival time |
| url | http://www.sciencedirect.com/science/article/pii/S2590006425000870 |
| work_keys_str_mv | AT linzhongyang bionicnanovesiclessequentiallytreatflapswithdifferentdurationsofischemiabythrombolysisandpreventionofischemiareperfusioninjury AT yuanchenliu bionicnanovesiclessequentiallytreatflapswithdifferentdurationsofischemiabythrombolysisandpreventionofischemiareperfusioninjury AT chengtao bionicnanovesiclessequentiallytreatflapswithdifferentdurationsofischemiabythrombolysisandpreventionofischemiareperfusioninjury AT zichencao bionicnanovesiclessequentiallytreatflapswithdifferentdurationsofischemiabythrombolysisandpreventionofischemiareperfusioninjury AT shilinguo bionicnanovesiclessequentiallytreatflapswithdifferentdurationsofischemiabythrombolysisandpreventionofischemiareperfusioninjury AT zhengwei bionicnanovesiclessequentiallytreatflapswithdifferentdurationsofischemiabythrombolysisandpreventionofischemiareperfusioninjury AT yanyiwang bionicnanovesiclessequentiallytreatflapswithdifferentdurationsofischemiabythrombolysisandpreventionofischemiareperfusioninjury AT taoliu bionicnanovesiclessequentiallytreatflapswithdifferentdurationsofischemiabythrombolysisandpreventionofischemiareperfusioninjury AT linchen bionicnanovesiclessequentiallytreatflapswithdifferentdurationsofischemiabythrombolysisandpreventionofischemiareperfusioninjury AT kexiong bionicnanovesiclessequentiallytreatflapswithdifferentdurationsofischemiabythrombolysisandpreventionofischemiareperfusioninjury AT xingyuluo bionicnanovesiclessequentiallytreatflapswithdifferentdurationsofischemiabythrombolysisandpreventionofischemiareperfusioninjury AT jianchuanran bionicnanovesiclessequentiallytreatflapswithdifferentdurationsofischemiabythrombolysisandpreventionofischemiareperfusioninjury AT weihan bionicnanovesiclessequentiallytreatflapswithdifferentdurationsofischemiabythrombolysisandpreventionofischemiareperfusioninjury |